3RD INTERNATIONAL WORKSHOP ON MICROBIOME IN...

www.virology-education.com

EVALUATION REPORT

3RD INTERNATIONAL WORKSHOP ON

ROCKVILLE, MD, USA • 19 - 20 OCTOBER 2017

MICROBIOME IN HIVPATHOGENESIS, PREVENTION AND TREATMENT

2Evaluation Report - 3rd International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 19-20 October 2017, Rockville, Maryland, USA

The third International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment was organized on the 19th and 20th October 2017 in Rockville, Maryland, USA. In total, there were 233 registrations from 30 countries.

The meeting features are multidisciplinary in nature, and significant in enabling the learning of how the host microbiome can influence responses to our current HIV therapies. In addition, this meeting will cultivate the participants’ ability to develop novel prevention and therapeutic strategies for HIV that will lead to the reduction of new HIV infections and the burden of non-communicable diseases in HIV infected individuals. Delegates will be provided with increased opportunities for discussion and exchange of knowledge following formal presentations of the latest research.

NEEDS ASSESSMENTA needs assessment was conducted on the first day of the event. 91% of the respondents reported that there is a need for a scientific program on the role of the Microbiome on HIV infection. The respondents also indicated that the major research gaps existing in the field include: prevention of HIV infection (23%), HIV treatment outcome (22%), and novel / innovative approaches (21%). Nearly 80% of the respondents (strongly) agreed that this year’s program met the mentioned research gaps.

INTENT TO USEAs reflected in the evaluation results, the conference was very well received. 100% of the respondents indicated that the lectures given in this workshop have increased their knowledge of the role of the microbiome in HIV pathogenesis, prevention and treatment; 96% agreed that the program was beneficial for their research; 96% reported that they intended to incorporate this new information into their research.

PROGRAMThe program included 14 invited lectures, 9 oral abstract presentations, and regular poster viewing sessions. Ample time was allocated for discussion. The evaluation scores of the presentations can be found on pages 14 - 20.

ABSTRACTSThe Organizing Committee received 25 abstracts, of which 9 were accepted for oral presentations, and all the abstract submitter were asked to present their data on a poster.

All abstracted were peer reviewed by the Organizing Committee. On average, each abstract was reviewed by 7 reviewers.

91% of the respondents reported that the poster session was a valuable element to the program; and 91% indicated that the combination of poster sessions and coffee breaks was well scheduled.

FUTUREThe majority of the respondents enjoyed the conference, of which 96% indicated that they would recommend the meeting to their colleagues and 100% plan to attend the 2018 meeting.

The Microbiome in HIV Workshop 2018 is scheduled to take place on the 16th and 17th October 2018 in Rockville, Maryland, USA.

EXECUTIVE SUMMARY

“Broad range of HIV/ Microbiome research, great discussion of new findings.”

“Cutting-edge studies were highlighted. Very informative workshop.”


Executive Summary .............................................................................. 2

Meeting Description .............................................................................. 5

Committees ........................................................................................... 6

Registrant Demographics ..................................................................... 8

Attendee Demographics ..................................................................... 11

Results of Needs Assessment ............................................................ 12

Results of Meeting Evaluation ............................................................ 13

Invited lectures, abstract-driven presentations ..................................14

Poster viewing ......................................................................................18

Intent to use ..........................................................................................18

Meeting objectives ................................................................................18

Learning objectives ...............................................................................18

Conference organization .......................................................................19

General conference experience ............................................................19

Participants’ remarks ...........................................................................20

Meeting Metrics .................................................................................. 21

Conclusion .......................................................................................... 22

Acknowledgements ............................................................................ 23

TABLE OF CONTENTS


BACKGROUNDThe understanding of the human microbiome continues to grow rapidly, however information on the role of the microbiome on HIV infection pathogenesis, prevention, and treatment is still limited. Whereas research in this area may be presented at major conferences, there are often limited sessions devoted to this topic as well as limited time for in-depth discussion and debate among cross-disciplinary experts on new data and their implications. The aim of this workshop is to provide increased opportunities for discussion and exchange of knowledge following formal presentations of the latest research.

MEETING OBJECTIVES

The objectives of this meeting are:

• To gather cross disciplinary professionals in the field of microbiome research to provide a better understanding of the impact of microbiome on host immunity.

• To develop a better understanding of how the microbiome effects the pathogenesis of HIV across mucosal sites.

• To use our knowledge of the microbiome field in developing novel strategies for developing microbicides / vaccine for HIV prevention.

FORMATThis 2 day event consists of invited lectures by experts, oral abstract presentations and poster presentations. Ample time is allocated for discussion.

UNIQUE MEETING FEATURESThe meeting features are multidisciplinary in nature, and significant in enabling the learning of how the host microbiome can influence responses to our current HIV therapies. In addition, this meeting will cultivate the participants’ ability to develop novel prevention and therapeutic strategies for HIV that will lead to the reduction of new HIV infections and the burden of non-communicable

diseases in HIV infected individuals.

TARGET AUDIENCEClinicians and researchers with interest in Microbiome in general, and in relation with HIV.

MEETING DESCRIPTION


COMMITTEES

ORGANIZING COMMITTEE

Angela Malaspina PhD

NIAID, USA

Rick Bushman PhD

University of Pennsylvania, USA

Que Dang PhD

NIAID, USA

Charles Boucher MD, PhD

Erasmus Medical Centre, the Netherlands

Alan Landay PhD

Rush University Medical Center, USA

Ron Collman PhD

University of Pennsylvania, USA

Stacy Carrington-Lawrence

PhD NIH, USA

Satya Dandekar PhD

University of California, Davis, USA

Nichole Klatt PhD

University of Washington, USA

Piotr Nowak MD, PhD

Karolinska University Hospital, Sweden

Roger Paredes MD, PhD

IrsiCaixa Foundation, Spain

Cara Wilson MD

University of Colorado, USA

Laurel Lagenaur PhD

NIH, USA


COMMITTEES

SCIENTIFIC COMMITTEE

INDUSTRY LIAISON BOARD

Shaun Barnabas, MD - University of Cape Town, South Africa

Jason Brenchley, MA, PhD - NIAID, USA

Andrea Gori, MD - University of Milano / San Gerardo Hospital, Italy

Catherine Lozupone, PhD - Denver University, USA

Jeanne Marrazzo, MD, MPH, FAC, FIDSA - The University of Alabama at Birmingham, USA

John McGowan, PhD - NIAID, USA

Nyaradzo Mavis Mgodi, MBChB, Mmed - University of Zimbabwe, Zimbabwe

Lita Proctor, PhD - National Institutes of Health, USA

Amalio Telenti, MD, PhD - J. Craig Venter Institute, USA

Angela Wahl, PhD - University of North Carolina at Chapel Hill, USA

Aaron Del Duca - DNA Genotek, Canada

James F. Demarest - ViiV Healthcare, USA

Howard D. Goldstein - GenapSys Inc., USA

Mohan S. Iyer - Whole Biome, USA

Gokul Swaminathan - Merck Research Laboratories, USA

Marc Tewey - ExeGi Pharma, USA

Michele Trucksis - Seres Therapeutics, USA


REGISTRANT DEMOGRAPHICS

This section outlines key statistical information of the meeting registrants. Registrants were those who had pre-registered for the workshop, but who did not necessarily attended the workshop.

NUMBER OF REGISTRATIONS• Pre-registrations: 185

• Onsite registrations: 18

• No shows: 80

GEOGRAPHICAL DISTRIBUTION OF REGISTRANTSThe registrations came from 30 countries. Most of them were from the United States (71.5%) followed by Nigeria (4.5%), and Canada (3%).

United States 145

Nigeria 9

Canada 6

South Africa 5

Cameroon 4

Malawi 3

Spain 3

Australia 2

Congo (DR) 2

Côte D’ivoire 2

Italy 2

Sweden 2

Austria 1

Benin 1

Brazil 1

Burkina Faso 1

Cambodia 1

Ethiopia 1

India 1

Indonesia 1

Iran 1

Japan 1

Kenya 1

Pakistan 1

Thailand 1

The Netherlands 1

Uganda 1

United Kingdom 1

Zambia 1

Zimbabwe 1



PROFESSIONAL BACKGROUND OF REGISTRANTS28% of the registrants work mainly as a researcher (PhD) and 18% as a medical doctor. 35% of the registrants indicated that they work in the area of HIV and 14% work in immunology.

Professional role(s) Area of expertise

N=255 (answers) out of 203 registrantsMultiple answers were allowed.

Others (N=51):

• Other (6%)

• Activist / Lobbyist (4%)

• Nurse (2%)

• Health Administrator (2%)

• Corporate Professional (1%)

• Laboratory Technician (1%)

• Patient Representative (1%)

• Pharmaceutical Company (1%)

• Resident (1%)

• Journalist (0.5%)

• Pharmacist (PharmD) (0.5%)

• Policy maker (0.5%)

• Medical Marketing Expert (0.5%)

• Pharmacologist (0.5%)


Others (N=94):

• Other (5%)

• Pediatrics (3%)

• Gynecology (3%)

• Liver Disease (3%)

• Dietology & Nutrition (2%)

• Hepatology (2%)

• Oncology (2%)

• Pharmacology (1%)

• Diabetology (1%)

• Gerontology (0.5%)

• Transplantology (0.5%)


Type of workplace Prescriber status


N=203 (answers) out of 203 registrants



ATTENDEE DEMOGRAPHICS

This section shows the number of participants who attended the event. During the meeting, they were asked to fill out a needs assessment survey, and evaluate each presentation, logistical arrangements, and overall event experience. Their responses and feedback can be found on the next pages.

NUMBER OF PARTICIPANTS123 participants attended the Microbiome in HIV Workshop 2017.

PERCENTAGE OF RETURNING AND NEW PARTICIPANTSN=31 (answers) out of 32 feedback forms.

68% of the respondents indicated that they were new to the workshop. 32% were returning attendees.

NUMBER OF PARTICIPANTS PER SESSION19 October 20 October

AMSession 4: 114

Session 1: 110 Session 5: 100

PMSession 2: 110 Session 6: 64

Session 3: 91


RESULTS OF NEEDS ASSESSMENT

A needs assessment was conducted on the first day of the event. 91% of the respondents reported that there is a need for a scientific program on the role of the Microbiome on HIV infection. The respondents also indicated that the major research gaps existing in the field include: prevention of HIV infection (23%), HIV treatment outcome (22%), and novel / innovative approaches (21%). Nearly 80% of the respondents (strongly) agreed that this year’s program met the mentioned research gaps.

Occupation of the respondents There is a need for a scientific program on the role of the Microbiome on HIV infection

N=53 (answers) out of 43 assessment forms Multiple answers were allowed.

N=34 (answers) out of 43 assessment forms; N/A=9

Which research gaps do you feel exist? This year’s program met the mentioned gaps indicated.

N=116 (answers) out of 43 assessment forms Multiple answers were allowed.

Others (N=4):• HIV Microbiome studies in Africa (resource limited setting)

• Virome analysis (microbiome)

• Role of microbiome in Aging & HIV infection

• Treatments, diets for gut managements in people with HIV

N=32 (answers) out of 43 assessment forms N/A=11


RESULTS OF MEETING EVALUATION

NUMBER OF RESPONDENTS PER DAY19 October 20 October

N=32 N=27

BACKGROUND OF RESPONDENTS46% of the respondents are researchers (PhD), followed by 24% medical doctors. 75% of the respondents work in a university, including (university) hospital. 25% of them reported that they work specifically in the field of microbiome in HIV.

Professional role(s) Area of expertise

N=70 (answers) out of 59 feedback forms Multiple answers were allowed.

Multiple answers were allowed. N=84 (answers) out of 60 feedback forms

Others (N=18):• Liver Disease (2%)

• Gerontology (2%)

• Gynecology (2%)

• GT (2%)

• Alcohol (1%)

• Milk (1%)

• Neurology (1%)

• HPV (1%)

• Epidemiology (1%)

• Mathematics/ Informatics (1%)

• Hepatitis (1%)

• Tuberculosis (1%)

Type of workplace

Multiple answers were allowed.N=57 (answers) out of 60 feedback forms



INVITED LECTURES, ABSTRACT-DRIVEN PRESENTATIONSTHURSDAY 19 OCTOBER

Opening lecture N=32

Brain-Gut-Microbiota interactions and intestinal health Wendy Henderson, USA

(Strongly) Agree Neither agree nor disagree

(Strongly) Disagree N/A

Topic is interesting 91% 9% 0% 0

Content is relevant to my work

50% 32% 18% 4

Session 1: Pathogenesis N=32

Mining adaptive immunity to identify disease-promoting microbiota members in HIV Ivan Vujkovic-Cvijin, USA





84% 16% 0% 1

Microbial colonization of thwe gut and brain development in infancy Rebecca Knickmeyer, USA





65% 22% 13% 3

Differential responses of colonic ILCs to gut commensal bacteria altered during HIV infection (Abstract # O_01) Moriah Castleman, USA





83% 14% 3% 3

Microbial dysbiosis does not alter immune activation or disease progression in SIV-infected rhesus macaques (Abstract # O_02) Alexandra Ortiz, USA





71% 21% 0% 4

Session 2: Transmission & Prevention N=32

Microbe: drug interactions and the impact on HIV infection and pathogenesis Nichole Klatt, USA





68% 23% 9% 0

Cervicovaginal microbial dynamics and its impact on HIV acquisition risk Douglas Kwon, USA





74% 13% 13% 0



Vaginal lactic acid inhibits production of pro-inflammatory mediators from human cervicovaginal epithelial cells associated with HIV acquisition (Abstract # O_03) Gilda Tachedjian, Australia





73% 20% 7% 1

Session 3: GI Tract and Diet N=32

Detrimental impact of a high fat diet on the natural history of SIV infection in non-human Ivona Pandrea, USA





71% 11% 18% 4

Milk - guiding the infant microbiome Bruce German, USA





72% 21% 7% 2

Understanding complexities of gut microbiome dysbiosis in HIV infected populations using a large cohort (Abstract # O_04) Abigail Armstrong, USA





73% 19% 8% 3

Plasma tryptophan-kynurenine metabolites are altered with gut microbiota dysbiosis in HIV infection and associated with progression of carotid artery atherosclerosis (Abstract # O_09) Qibin Qi, USA





79% 16% 5% 3



FRIDAY 20 OCTOBER Session 4: Comorbidities N=27

Microbial metabolites in HIV pathogenesis and comorbidities Dana Gabuzda, USA





84% 13% 3% 0

Session 5: Session 5: Microbiome & Vaccines N=27

Aging, the microbiome and vaccine responses Daria Hazuda, USA





73% 10% 17% 1

Mechanisms intersecting microbiota metabolomics with gut epithelial barrier repair in HIV infection Satya Dandekar, USA





84% 16% 0% 1

Role of the microbiome in HIV vaccine response heterogeneity James Kublin, USA





52% 31% 17% 1

Effect of high-risk sexual behaviour on diversity of the vaginal microbiota and abundance of lactobacillus (Abstract # O_06) Jocelyn Wessels, Canada





72% 28% 0% 1



Session 6: Metabolomics Biologic and Technical Issues N=27

Studying the functional microbiome in vivo in HIV by metaproteomics approaches Adam Burgener, Canada





79% 21% 0% 1

Fatty acid profiles differ in HIV infection, persist despite suppressive ART, and are associated with immune activation Nicholas Funderburg, USA





75% 15% 10% 0

Modulation of gut microbiota by indoleamine 2,3-dioxygenase 1 inhibitor during antiretroviral suppressed SIV infection in rhesus macaques (Abstract # O_07) Zhang Wang, USA





79% 14% 7% 2

The microbial-derived short chain fatty acid butyrate directly and differentially inhibits gut T helper cell subset activation and proliferation (Abstract # O_08) Jon Kibbie, USA





84% 16% 0% 3


POSTER VIEWING

N=32

(Strongly) Agree Neither agree nor

disagree


The poster session was a valuable element to the program 91% 9% 0% 1

The combination of the poster sessions and breaks were well scheduled 91% 9% 0% 1

INTENT TO USE

N=27


disagree


The lectures given in this workshop have increased my knowledge of microbiome in HIV pathogenesis, prevention and treatment

100% 0% 0% 0

This program is beneficial for my research 96% 4% 0% 1

I intend to incorporate the new information into my research 96% 4% 0% 1

MEETING OBJECTIVES

N=27(Strongly) Agree Neither agree nor

disagree


To gather cross disciplinary professionals in the field of microbiome research to provide a better understanding of the impact of microbiome on host immunity

100% 0% 0% 0

To develop a better understanding of how microbiome effects the pathogenesis of HIV across mucosal sites

96% 4% 0% 0

To use our knowledge of the microbiome field in developing novel strategies for developing microbicides /vaccine for HIV prevention.

86% 14% 0% 2

LEARNING OBJECTIVES

N=27(Strongly) Agree Neither agree nor

disagree


To recall the complex interplay between the human microbiome, host immunity and pathogenesis

100% 0% 0% 0

To translate research achievements to challenges for the development of preventive approaches to reduce virus transmission

87% 13% 0% 1



COFERENCE ORGANIZATIONN=32 (Very) Good Average (Very) Poor N/A

Content of electronic announcements (newsletters) 100% 0% 0% 5

Frequency of electronic announcements (newsletters) 96% 4% 0% 5

Information on the conference website 94% 6% 0% 0

Online registration process 94% 0% 6% 0

Online abstract submission process 100% 0% 0% 14

Meeting venue 91% 3% 6% 0

Meeting room 83% 11% 6% 1

Audiovisuals 90% 7% 3% 0

Food & Beverage 71% 22% 7% 4

Onsite logistics 90% 7% 3% 2

Service level of Conference Secretariat 100% 0% 0% 2

GENERAL CONFERENCE EXPERIENCE N=27 (Very) Good Average (Very) Poor N/A

Overall event experience 100% 0% 0% 0

Opportunity of networking 79% 21% 0% 0

Content of the educational activity 100% 0% 0% 0

Time allocation for discussion 91% 5% 4% 0

Time allocation per presentation 96% 4% 0% 0


disagree


No commercial bias (product selling) perceived 100% 0% 0% 1

I would recommend this educational event to my peers 96% 4% 0% 0

I plan to attend this event next time 100% 0% 0% 0



PARTICIPANTS’ REMARKS• Ground-breaking information and cutting edge.

• Cutting-edge studies are highlighted. Very informative workshop.

• Cutting edge.

• Overview of microbiome in HIV-infected subjects.

• Broad range of HIV/Microbiome research, great discussion of new findings.

• A great small and comprehensive venue to learn and network regarding HIV and the Microbiome.

• Non-disciplinary.

• Great.

• Very informative.

• Very interesting, good networking opportunity.

• Great! Well worth attending.

• Great workshop! Thank you.

• Loved session 5.

• Excellent time allocation.



How did you become aware of this workshop: I was motivated to attend this meeting because of:

N=31 (answers) out of 32 feedback formsMultiple answers were allowed.

N=62 (answers) out of 32 feedback formsMultiple answers were allowed.

Others (N=2):• Announcement at work (email) (3%)

• Web search (google) (3%)

Others (N=2):• Repeated phone calls

• Colleague was going

MEETING METRICS


The Organizing Secretariat and Committee are pleased with the results of the third International Workshop

on Microbiome in HIV Pathogenesis, Prevention and Treatment. Most of the participants were impressed by

the quality of the scientific content and the time allocation for the discussions. The majority also reported

that they were satisfied with the overall meeting logistical arrangements and agreed it was a well-organized

event. Both the evaluation results and the participants’ feedback proved the success and the importance

of this event. The Organizing Committee will further discuss the preparation and the development of the

scientific program for the 4th edition in 2018, scheduled to take place on the 16th and 17th October in Rockville,

Maryland, USA.

CONCLUSION

“Ground-breaking information and cutting edge.

“Very interesting, good networking opportunity.


ACKNOWLEDGEMENTS

SPONSORS

TITANIUM LEVEL

SUPPORTER LEVEL

CONTRIBUTOR LEVEL


ACKNOWLEDGEMENTS

ENDORSERS

This meeting was supported by the National Institutes of Health.

SUPPORTER

www.virology-education.com

3RD INTERNATIONAL WORKSHOP ON MICROBIOME IN...

Documents

Transcript of 3RD INTERNATIONAL WORKSHOP ON MICROBIOME IN...